Primary Progressive Multiple Sclerosis: New Therapeutic Approaches
Neuropsychopharmacology Reports · 2025-09 · 45 (3)
DOI: 10.1002/npr2.70039 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Neuropsychopharmacology Reports, online erschienen am 13.07.2025. Verfasst von Morteza Rajabi und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Genetics, Faculty of Basic Sciences, Central Tehran Branch, Islamic Azad University, Tehran, Iran. Hauptthemen laut MEDLINE: Multiple Sclerosis, Chronic Progressive. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 313 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background and Purpose Primary progressive multiple sclerosis (PPMS) is a clinically different form of MS that causes gradual and irreversible neurological impairment from symptom onset without relapses or remissions. With a mean onset age of 37–43 years, PPMS affects 10%–15% of MS patients and presents distinct diagnostic and treatment issues. Mobility issues, persistent pain, sensory disturbances, cognitive deficits, and bowel and bladder problems intensify over time. Neuroimaging shows substantial brain and spinal cord atrophy with fewer brain lesions but more spinal cord lesions.
Findings
Drugs like ocrelizumab reduce progression, whereas high‐dose biotin, simvastatin, and coenzyme Q10 are being investigated. PPMS treatment is difficult, with continuing research on fingolimod, idebenone, anti‐LINGO‐1, neuromodulation, and plasmapheresis. Ocrelizumab has shown encouraging outcomes. Preclinical gene therapy studies on immune regulation, neuroprotection, and remyelination in MS animals show promise. Hematopoietic and non‐hematopoietic stem cell therapies have also been studied for their capacity to reduce neuroinflammation, repair tissue, and boost neurotrophic support.
Conclusions
Clinical research utilizing human fetal neural precursor cells (hfNPCs) reveals neuroprotective advantages and opportunities for PPMS treatment. Early clinical trials have shown promising results, but more study is needed to prove the safety and usefulness of these new PPMS treatments.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Genetics, Faculty of Basic Sciences, Central Tehran Branch, Islamic Azad University, Tehran, Iran.
- Shared Health - Northern Regional Health Authority (NRHA), Flin Flon, Manitoba, Canada.
- Department of Clinical Biochemistry, School of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran.
- Department of Medical Genetics, School of Advanced Technologies in Medicine, Golestan University of Medical Sciences, Gorgan, Iran.
- Department of Medical Genetics and Molecular Medicine, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
- Department of Microbiology, Islamic Azad University of Damghan, Damghan, Iran.
ORCID-Profile: Ehsan Saburi
Zitieren
APA
Rajabi, M., Shafaeibajestan, S., Asadpour, S., Alyari, G., Taei, N., Kohkalani, M., Raoufinia, R., Afarande, H., & Saburi, E. (2025). Primary Progressive Multiple Sclerosis: New Therapeutic Approaches. Neuropsychopharmacology Reports, 45(3). https://doi.org/10.1002/npr2.70039
Vancouver
Rajabi M, Shafaeibajestan S, Asadpour S, Alyari G, Taei N, Kohkalani M, et al. Primary Progressive Multiple Sclerosis: New Therapeutic Approaches. Neuropsychopharmacology Reports. 2025;45(3). doi:10.1002/npr2.70039
BibTeX
@article{Rajabi2025,
author = {Rajabi, Morteza and Shafaeibajestan, Sajjad and Asadpour, Sevda and Alyari, Ghazal and Taei, Niloofar and Kohkalani, Moein and Raoufinia, Ramin and Afarande, Hamed and Saburi, Ehsan},
title = {Primary Progressive Multiple Sclerosis: New Therapeutic Approaches},
journal = {Neuropsychopharmacology Reports},
year = {2025},
volume = {45},
number = {3},
doi = {10.1002/npr2.70039}
}
EUVIMED